Syzygium cumini (L.) Skeels (syn. S. jambolanum DC, Eugenia jambolana Lam.) belongs to the medicinal plants most often recommended as an adjuvant therapy in type 2 diabetes. The plant was extensively studied during the last 125 years, approximately 100 case reports
were reported already before the discovery of insulin. After the Second World War, research was concentrated on animal studies. Not all, but many of them reported some success in reducing type 2 diabetes symptoms. However, a state-of-the-art clinical study is still missing. In this review,
historical literature dating back to the pre-insulin era was evaluated as were more recent in vitro-, animal-, and in vivo studies. Results were screened for information still useful today and compared to study results achieved in more recent decades. In view of the knowledge
summarized here, a successful clinical study should use S. cumini seeds, seed kernels or fruit from India in fairly high doses. Reductions on blood sugar levels by about 30% seem reasonably to be expected. Adverse effects to be expected comprise gastrointestinal disturbances.
No References for this article.
No Supplementary Data.
No Article Media
Document Type: Research Article
Institute for the History of Pharmacy, Philipps-University, Roter Graben 10, Marburg, D-35032, Germany, Email: [email protected]
Institute for the History of Pharmacy, Philipps-University, Carl-Mannich-Str. 26, Eschborn, D-65760, Germany, Email: [email protected]
February 1, 2008
More about this publication?
Pharmazie is a leading journal in the field of pharmaceutical sciences. As a peer-reviewed scientific journal, Pharmazie is regularly indexed in the relevant databases like Web of science, Journal Citation Reports and many others. The journal is open for submissions from the whole spectrum of pharnaceutical sciences including Pharmaceutical Chemistry, Experimental and Clinical Pharmacology, Drug Analysis, Pharmaceutics, Pharmaceutical Biology, Clinical Pharmacy etc.
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites